+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Non-Injectable Insulin

  • PDF Icon

    Report

  • 54 Pages
  • January 2020
  • Region: Global
  • BCC Research
  • ID: 4912193
UP TO OFF until Aug 31st 2033

Report Scope:

The report provides a comprehensive summary of the Non-injectable insulin market, along with detailed profiles of key market players that include revenue product portfolios and recent activities. The report analyzes trends and dynamics, including drivers, limitations, challenges and opportunities. The report discusses strategies adopted by emerging market players, with recommendations for new market entrants. This research study discusses historical, current and potential market size. The report will help market players and new entrants make informed decisions about the production and export of goods and services. Organizations, distributors and exporters should find the information about market development and trends useful. The study segments the market according to applications and end-uses. Geographical market analysis is provided for all major segments.

The Report Includes:


  • An overview of the global market for non-injectable insulin
  • Analyses of market trends, with data from 2018, 2019, and projections of compound annual growth rates (CAGRs) through 2024
  • Information on recent major technical advances in different forms of non-injectable insulin
  • A look at the key areas of growth and adoption rate of non-injectable insulin among both commercial customers and regulatory authorities
  • Examination of strategies of the major players in the market and the impact of new technological developments

Table of Contents

Chapter 1 Introduction
  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related Reports


Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
  • Future Market Potential and Investment Analysis
  • North America Will be the Largest and Fastest-Growing Market


Chapter 4 Market Breakdown by Form
  • Pills
  • Spray
  • Others (Film and Chewing Gum)


Chapter 5 Market Breakdown by Source
  • Synthetic Insulin
  • Semisynthetic Insulin


Chapter 6 Market Breakdown by Region
  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • China
  • India
  • Japan
  • Rest of Asia-Pacific
  • Rest of the World


Chapter 7 Competitive Landscape
Chapter 8 Company Profiles
  • Access Pharmaceuticals Inc. (Abeona Therapeutics Inc.)
  • Aerami Therapeutics
  • Biocon Ltd.
  • Biodel Inc. (Albireo Ltd.)
  • Bionova Lifesciences
  • Boston Therapeutics Inc.
  • Coromed Inc.
  • Diabetology Ltd.
  • Diasome Pharmaceuticals Inc.
  • Emisphere Technologies Inc.
  • Generex Biotechnology Corp.
  • Midatech Pharma Plc
  • Oramed Pharmaceuticals Inc.
  • Rani Therapeutics
  • Shreya Life Sciences Pvt. Ltd.


List of Tables
Summary Table: Global Market for Non-injectable Insulin, by Region, Through 2024
Table 1: Other Products Related to Non-injectable Insulin
Table 2: Examples of Non-injectable Insulin Products
Table 3: Global Market for Non-injectable Insulin, by Form, Through 2024
Table 4: Global Market for Edible Insulin Pills, by Region, Through 2024
Table 5: Global Market for Insulin Sprays, by Region, Through 2024
Table 6: Global Market for Other Forms of Non-injectable Insulin, by Region, Through 2024
Table 7: Global Market for Non-injectable Insulin, by Source, Through 2024
Table 8: Global Market for Synthetic Non-injectable Insulin, by Region, Through 2024
Table 9: Global Market for Semisynthetic Non-injectable Insulin, by Region, Through 2024
Table 10: Global Market for Non-injectable Insulin, by Region, Through 2024
Table 11: Top 10 Countries with the Highest Prevalence of Diabetes Across the Globe, 2019
Table 12: North American Market for Non-injectable Insulin, by Form, Through 2024
Table 13: North American Market for Non-injectable Insulin, by Source, Through 2024
Table 14: Prevalence of Diabetes in North American Countries, 2010-2017
Table 15: Prevalence of Diabetes in North America, 2019-2045
Table 16: Prevalence of Diabetes in Europe, 2019-2045
Table 17: European Market for Non-injectable Insulin, by Form, Through 2024
Table 18: European Market for Non-injectable Insulin, by Source, Through 2024
Table 19: Existing National Diabetes Plans in Europe, by Country
Table 20: Prevalence of Diabetes in Asia-Pacific, 2019-2045
Table 21: Asia-Pacific Market for Non-injectable Insulin, by Form, Through 2024
Table 22: Asia-Pacific Market for Non-injectable Insulin, by Source, Through 2024
Table 23: Rest of the World Market for Non-injectable Insulin, by Form, Through 2024
Table 24: Rest of the World Market for Non-injectable Insulin, by Source, Through 2024
List of Figures
Summary Figure: Global Market for Non-injectable Insulin, by Region, 2018-2024
Figure 1: Global Prevalence of Diabetes in the 20-79 Year Age Group, 2011-2045*
Figure 2: Global Diabetes Prevalence, 2019-2045
Figure 3: Novo Nordisk Revenue Share, by Region, 2018
Figure 4: Eli Lilly Revenue Share, by Segment, 2018
Figure 5: Nektar Therapeutics Revenue Share, by Region, 2018

Samples

Loading
LOADING...

Executive Summary

This comprehensive report provides an in-depth assessment of the global market for Non-injectable insulin. The report’s key objective is to analyze areas of opportunities, key developments and the impact of this technology on industry, specifically the pharmaceutical, biotechnology and healthcare sectors. The analysis also reviews the adoption of Non-injectable insulin in developed and emerging markets.

This report details recent key technical advances in different forms of Non-injectable insulin, as well as the adoption rate among both commercial customers and regulatory authorities. The report intends to identify key areas of growth. The report also studies the key strategies of major players in the market and the impact of new technological developments.


Companies Mentioned

  • Access Pharmaceuticals Inc. (Abeona Therapeutics Inc.)
  • Aerami Therapeutics
  • Biocon Ltd.
  • Biodel Inc. (Albireo Ltd.)
  • Bionova Lifesciences
  • Boston Therapeutics Inc.
  • Coromed Inc.
  • Diabetology Ltd.
  • Diasome Pharmaceuticals Inc.
  • Emisphere Technologies Inc.
  • Generex Biotechnology Corp.
  • Midatech Pharma Plc
  • Oramed Pharmaceuticals Inc.
  • Rani Therapeutics
  • Shreya Life Sciences Pvt. Ltd.